Emergingdx Inc.

Emergingdx Inc., a Lowell, Massachusetts-based small business operating as a Subchapter S corporation, develops advanced diagnostic and biosensor platforms for rapid pathogen identification and biomarker detection as a prime contractor under small-business set-asides, competing exclusively in federal R&D programs rather than through open competitive or larger vehicle-based channels.

The company's federal footprint centers on SBIR and STTR research contracts from defense and agricultural agencies. Across 13 prime awards totaling $8.9 million in combined potential value, Emergingdx operates exclusively in small-business set-aside R&D competitions — no sub-award footprint, no participation on government-wide vehicles or IDIQs, and no sub-contracting relationships. The Defense Health Agency dominates the customer concentration, accounting for nine awards and $6.4 million of potential value, with the Office of Naval Research contributing three awards worth $2.5 million. A single Department of Agriculture National Institute of Food and Agriculture grant rounds out the customer set. The vendor's capability portfolio reflects deep specialization in multiplexed diagnostic platforms: recent named work includes a $1.3 million Defense Health Agency Phase II SBIR contract (awarded July 2026, completing October 2028) for an integrated multiplexed low-cost diagnostic platform for rapid microbial identification at the Lowell facility; a $2 million Office of Naval Research R&D definitive contract (September 2025, cost-plus-fixed-fee, completing October 2029) on advanced diagnostic and biosensor technologies; a $1.3 million DHA Phase II SBIR award (September 2025, completing January 2028) for a rapid, automated, multiplexed omics platform; and a $1.3 million DHA Phase II STTR contract (February 2025, completing June 2027) for a multiplexed diagnostic platform targeting invasive fungal infection. Earlier-stage Phase I SBIR and STTR awards, each valued near $250 thousand, explored multiplexed biosensors, circulating microRNA detection, and omics-based platforms. The vendor also holds a Department of Agriculture grant (awarded July 2023, completing February 2025) focused on Flavobacterium psychrophilum diagnostics for salmonid aquaculture.

Activity has grown modestly from one award in 2022 to four awards annually in 2024 and 2025. Three awards carrying combined potential value of $3.9 million face ultimate completion within the next twenty-four months, signaling near-term recompete exposure across DHA and ONR SBIR/STTR competitions. The company performs R&D work across Lowell and Mansfield, Massachusetts facilities with no major subcontractor engagement, indicating vertical integration of diagnostic platform development. The vendor's competitive posture remains narrowly focused on small-business R&D set-asides; growth trajectory and pipeline depend on continued DHA and ONR SBIR/STTR topic selection and Phase continuation funding rather than on scaling through larger vehicle-based programs.

Research and Development, Product and Technology Development, Commercialization, Venturing